NASDAQ: EOLSEvolus Inc Stock Ownership - Who owns Evolus?
Insider buying vs selling
Have Evolus Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David Moatazedi | CEO;Pres | 2026-09-02 | 105,108 | $9.04 | $950.07kSell |
| David Moatazedi | President Chief Executive Officer | 2026-03-20 | 13,669 | $4.75 | $64.93kSell |
| Rui Avelar | Officer | 2026-03-20 | 3,119 | $4.75 | $14.82kSell |
| Rui Avelar | Chief Medical Officer and Head of Research Development | 2026-03-17 | 29,996 | $4.89 | $146.62kSell |
| David Moatazedi | President and Chief Executive Officer | 2026-03-17 | 116,720 | $4.89 | $570.53kSell |
| David Moatazedi | President and Chief Executive Officer | 2025-12-22 | 10,539 | $7.15 | $75.36kSell |
| Rui Avelar | Chief Medical Officer Head of Research and Development | 2025-12-22 | 2,261 | $7.15 | $16.17kSell |
EOLS insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when EOLS insiders and whales buy or sell their stock.
EOLS Shareholders
What type of owners hold Evolus Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Medytox Inc | 16.11% | 10,640,826 | $84.17M | Insider |
| Alphaeon 1 LLC | 6.38% | 4,214,871 | $33.34M | Insider |
| Simone Blank | 0.85% | 559,894 | $4.43M | Insider |
| David Moatazedi | 0.76% | 499,592 | $3.95M | Insider |
| Rui Avelar | 0.65% | 427,423 | $3.38M | Insider |
| Vikram Malik | 0.49% | 321,109 | $2.54M | Insider |
| Tatjana Mitchell | 0.34% | 226,092 | $1.79M | Insider |
| Michael M. Jafar | 0.33% | 219,851 | $1.74M | Insider |
| Sandra Beaver | 0.25% | 167,089 | $1.32M | Insider |
| Lauren P. Silvernail | 0.21% | 141,571 | $1.12M | Insider |
EOLS vs Pharmaceutical Stocks
Evolus Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.